Cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has revolutionized personalized treatment of metastatic colorectal cancer (mCRC) patients. This review highlights the mechanism of action, characteristics, and optimal indications for cetuximab in mCRC. Cetuximab has emerged as a pivotal partner for novel therapies in specific molecular subgroups, includingBRAFV600E,KRASG12C, and HER2-altered mCRC. Combining cetuximab with immunotherapy and other targeted agents further expands the therapeutic landscape, offering renewed hope for mCRC patients who face the development of resistance to conventional therapies. Ongoing clinical trials have continued to uncover innovative cetuximab-based treatment strategies, promising a brighter future for mCRC patients. This review provides a comprehensive overview of cetuximab’s role and its evolving importance in personalized targeted therapy of mCRC patients, offering valuable insights into the evolving landscape of colorectal cancer treatment.
西妥昔单抗是一种靶向表皮生长因子受体（EGFR）的嵌合IgG1单克隆抗体，其应用已彻底改变了转移性结直肠癌（mCRC）患者的个体化治疗模式。本综述重点阐述西妥昔单抗在mCRC治疗中的作用机制、药物特性及最佳适应症。在特定分子亚群（包括BRAFV600E、KRASG12C及HER2变异型mCRC）中，西妥昔单抗已成为新型治疗方案的关键组成部分。该药物与免疫疗法及其他靶向药物的联合应用进一步拓展了治疗前景，为传统疗法产生耐药性的mCRC患者带来新的希望。当前正在进行的临床试验持续揭示以西妥昔单抗为基础的创新治疗策略，预示着mCRC患者将迎来更光明的治疗前景。本综述系统阐述了西妥昔单抗在mCRC个体化靶向治疗中的作用及其日益凸显的重要性，为结直肠癌治疗格局的演进提供了重要见解。
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
肿瘤(癌症)患者之家